- Home
- USEG vs CLSD Comparison
USEG vs CLSD Comparison
Compare USEG & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEG
- CLSD
- Stock Information
- Founded
- USEG 1966
- CLSD 2011
- Country
- USEG United States
- CLSD United States
- Employees
- USEG N/A
- CLSD N/A
- Industry
- USEG Oil & Gas Production
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- USEG Energy
- CLSD Health Care
- Exchange
- USEG Nasdaq
- CLSD Nasdaq
- Market Cap
- USEG 68.6M
- CLSD 81.2M
- IPO Year
- USEG N/A
- CLSD 2016
- Fundamental
- Price
- USEG $1.95
- CLSD $0.95
- Analyst Decision
- USEG Strong Buy
- CLSD Strong Buy
- Analyst Count
- USEG 2
- CLSD 6
- Target Price
- USEG $2.75
- CLSD $5.33
- AVG Volume (30 Days)
- USEG 4.2M
- CLSD 214.9K
- Earning Date
- USEG 03-25-2025
- CLSD 03-11-2025
- Dividend Yield
- USEG N/A
- CLSD N/A
- EPS Growth
- USEG N/A
- CLSD N/A
- EPS
- USEG N/A
- CLSD N/A
- Revenue
- USEG $22,257,000.00
- CLSD $7,703,000.00
- Revenue This Year
- USEG N/A
- CLSD N/A
- Revenue Next Year
- USEG $12.17
- CLSD $91.87
- P/E Ratio
- USEG N/A
- CLSD N/A
- Revenue Growth
- USEG N/A
- CLSD 248.39
- 52 Week Low
- USEG $0.81
- CLSD $0.80
- 52 Week High
- USEG $6.40
- CLSD $2.12
- Technical
- Relative Strength Index (RSI)
- USEG 43.97
- CLSD 43.06
- Support Level
- USEG $2.03
- CLSD $1.00
- Resistance Level
- USEG $2.17
- CLSD $1.09
- Average True Range (ATR)
- USEG 0.22
- CLSD 0.07
- MACD
- USEG -0.05
- CLSD -0.01
- Stochastic Oscillator
- USEG 0.00
- CLSD 16.30
About USEG U.S. Energy Corp. (DE)
US Energy Corp is an independent energy company. It is focused on the acquisition and development of oil and natural gas-producing properties in the continental United States. It has business activities in South Texas and the Williston Basin in North Dakota. The company generates revenue from its interest in the sales of oil and natural gas production.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.